La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Zealand Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Zealand Pharma..

Zealand Pharma (OTC:ZLDPF) Azioni, Catena delle Opzioni

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

ZEALAND PHARMA A/S ORD by Zealand Pharma A/S

Zealand Pharma AS

Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Weight loss drug developers slump as Eli Lilly slashes cost of some Zepbound doses

Novo Nordisk warns of continued Ozempic shortage in Q4

Terns stock jumps as weight loss drug succeeds in early trial

Jefferies analyst Lucy Codrington maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) today and set a price target of DKK1,100.00. ...

Jefferies Sticks to Their Buy Rating for Zealand Pharma (ZLDPF)

Catalyst Watch: Tesla's Robotaxi reveal, AI events for Nvidia, AMD, and HP Enterprise

Zealand Pharma A/S ( ($ZLDPF) ) has released its Q3 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its investors....

Zealand Pharma's 2024 Progress and Financial Results

JPMorgan initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 1,100 price target The firm cites the company's obesity pip...

Zealand Pharma initiated with an Overweight at JPMorgan

Danske Bank upgraded Zealand Pharma (ZLDPF) to Hold from Sell with an DKK 825 price target Published first on TheFly – the ultimate source for real...

Comments

Zealand Pharma

Zealand Pharma (ZLDPF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO